Related Experiment Video
Updated: Oct 25, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Greyzone myocardial fibrosis and ventricular arrhythmias in patients with a left ventricular ejection fraction >35
Abbasin Zegard1,2, Osita Okafor1,2, Joseph de Bono2
1Aston Medical School, Aston University, Birmingham, UK.
Insights
Greyzone fibrosis (GZF) on cardiovascular magnetic resonance (CMR) strongly predicts ventricular arrhythmias in coronary artery disease (CAD) patients with preserved ejection fraction. This finding aids in identifying high-risk individuals for sudden cardiac events.
Area of Science:
- Cardiovascular Imaging
- Cardiac MRI
- Myocardial Fibrosis
Background:
- Myocardial fibrosis is a key substrate for ventricular arrhythmias.
- Greyzone fibrosis (GZF) represents an intermediate stage of fibrosis.
- Its role in patients with coronary artery disease (CAD) and preserved ejection fraction requires further elucidation.
Purpose of the Study:
- To investigate the association between GZF and ventricular arrhythmias.
- To assess cardiovascular magnetic resonance (CMR) findings in patients with CAD and left ventricular ejection fraction (LVEF) >35%.
Main Methods:
- Retrospective analysis of 701 CAD patients with LVEF >35%.
- Quantification of GZF mass (GZF3SD) and total fibrosis mass (TF2SD) using CMR.
- Evaluation of association with a composite endpoint of sudden cardiac death, ventricular tachycardia, or fibrillation.
Main Results:
- A GZF3SD mass ≥5.0 g was strongly associated with the arrhythmic endpoint (sHR: 17.4, AUC: 0.85).
- TF2SD mass ≥23 g showed a weaker association (sHR: 10.4, AUC: 0.80).
- GZF3SD demonstrated a wider range of hazard ratios compared to TF2SD.
Conclusions:
- In CAD patients with LVEF >35%, GZF mass on CMR is a strong predictor of arrhythmic events.
- GZF quantification holds promise for risk stratification in this patient population.
- These findings may improve identification of patients at risk for sudden cardiac death.
Aims:
To determine whether myocardial fibrosis and greyzone fibrosis (GZF) on cardiovascular magnetic resonance (CMR) is associated with ventricular arrhythmias in patients with coronary artery disease (CAD) and a left ventricular ejection fraction (LVEF) >35%.
Methods And Results:
In this retrospective study of CAD patients, GZF mass using the 3SD method (GZF3SD) and total fibrosis mass using the 2SD method (TF2SD) on CMR were assessed in relation to the primary, combined endpoint of sudden cardiac death, ventricular tachycardia, ventricular fibrillation, or resuscitated cardiac arrest. Among 701 patients [age: 65.8 ± 12.3 years (mean ± SD)], 28 (3.99%) patients met the primary endpoint over 5.91 years (median; interquartile range 4.42-7.64). In competing risks analysis, a GZF3SD mass ≥5.0 g was strongly associated with the primary endpoint [subdistribution hazard ratio (sHR): 17.4 (95% confidence interval, CI 6.64-45.5); area under receiver operator characteristic curve (AUC): 0.85, P < 0.001]. A weaker association was observed for TF2SD mass ≥23 g [sHR 10.4 (95% CI 4.22-25.8); AUC: 0.80, P < 0.001]. The range of sHRs for GZF3SD mass (1-527) was wider than for TF2SD mass (1-37.6).
Conclusions:
In CAD patients with an LVEF >35%, GZF3SD mass was strongly associated with the arrhythmic endpoint. These findings hold promise for its use in identifying patients with CAD and an LVEF >35% at risk of arrhythmic events.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
Myocarditis I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Heart Failure II: Pathophysiology
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy